Bye bye Ozempic: Eli Lilly says its new drug retatrutide more than doubles weight loss

Eli Lilly's experimental drug retatrutide has shown to more than double weight loss compared to Ozempic in clinical trials, positioning it as a promising next-generation treatment for obesity and diabetes. The drug, still in development, outperformed Ozempic in a head-to-head study. Retatrutide is a triple-action injectable targeting weight loss and metabolic health.